The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
Open accessAbstract
Apolipoprotein (apo) E4, a 299-aa protein and a major risk factor for Alzheimer's disease, can be cleaved to generate C-terminal-truncated fragments that cause neurotoxicity in vitro and neurodegeneration and behavioral deficits in transgenic mice. To investigate this neurotoxicity, we expressed apoE4 with C- or N-terminal truncations or mutations in transfected Neuro-2a cells. ApoE4 (1-272) was neurotoxic, but full-length apoE4(1-299) and apoE4(1-240) were not, suggesting that the lipid-binding region (amino acids 241-272) mediates the neurotoxicity and that amino acids 273-299 are protective. A quadruple mutation in the lipid-binding region (I250A, F257A, W264R, and V269A) abolished the neurotoxicity of apoE4(1-272), and single mutations in the region of amino acids 273-299 (L279Q, K282A, or Q284A) made full-length apoE4 neurotoxic. Immunofluorescence staining showed that apoE4(1-272) formed filamentous inclusions containing phosphorylated tau in some cells and interacted with mitochondria in others, leading to mitochondrial dysfunction as determined by MitoTracker staining and flow cytometry. ApoE4(241-272) did not cause mitochondrial dysfunction or neurotoxicity, suggesting that the lipid-binding region alone is insufficient for neurotoxicity. Truncation of N-terminal sequences (amino acids 1-170) containing the receptor-binding region (amino acids 135-150) and triple mutations within that region (R142A, K146A, and R147A) abolished the mitochondrial interaction and neurotoxicity of apoE4(1-272). Further analysis showed that the receptor-binding region is required for escape from the secretory pathway and that the lipid-binding region mediates mitochondrial interaction. Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 increases the sensitivity of cells to oxidative stress”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the generation of a toxic C-terminal fragment of apoE4 that can directly target electron transport chain (ETC) complexes in the mitochondria25–27”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the molecular level, ApoE4 has been associated with aggravated AD neuropathology, enhanced neuroinflammation, deregulated lipid metabolism, mitochondrial dysfunction, and impaired synaptic plasticity (Nagy et al., 1995;Chang et al., 2005;Rapp et al., 2006;Klein et al., 2010;Rodriguez et al., 2014).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Chang et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“expression of fragments containing this domain in N2a cells results in neurotoxicity [17]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and cause mitochondrial fragmentation [10, 17, 20]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest apoE4 fragment, apoE4(1–272), interacts directly with mitochondria to reduce mitochondrial membrane potential”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurons, apoE4 is associated with impaired mitochondrial respiration”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies on the trafficking of APOE have also suggested that the cleaved C-terminus of APOE can exist in the cytoplasm and associate with mitochondria in neurons (Chang et al., 2005).”
From APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size (2024) · cites this paper as Chang et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and in higher levels than in age- and sex-matched controls [29].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE4 largest fragment (1–272 aa) was shown to directly interact with mitochondria, which leads to a decrease in Δψm and mitochondrial fragmentation [26,29,73].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Limited data suggest that a particular fragment of apoE (1–272 amino acids) can translocate to cytosol and interacts with cytoskeletal proteins (Chang et al., 2005).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Chang et al., 2005
The cited source says what the claim attributes to it.
In the citing paper
“These and other findings suggest that not all apoE4 forms found in the brains of AD patients are equally bioactive and that specific apoE4 forms may be involved in processes associated with AD pathogenesis (10, 14 -17).”
From Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4 (2014) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“In vitro studies have shown that fragments of APOE, which are more abundant with APOE4 than with APOE3, can cause neuronal mitochondrial dysfunction165,166.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [165]
The cited source says what the claim attributes to it.
In the citing paper
“apoE4 (1-272) fragment appears to interact directly with mitochondria, resulting in mitochondrial dysfunction and neurotoxicity [13]”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Available literature also shows that apoE4 (1-272) fragments can directly interact with mitochondria, causing mitochondrial dysfunction and neurotoxicity [13].”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The resulting apoE fragments escape the secretory pathway into the cytosol”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“and neurotoxicity [10, 17–19, 34, 35]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Although apoE fragments interact directly with mitochondria and disrupt their function [17, 20]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The interaction of apoE4 fragments with mitochondria is dependent on the apoE lipid-binding domain”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“where they engage in abnormal interactions that lead to neurodegeneration [17–19]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“some studies in N2a cells demonstrated that ApoE4 N-terminal fragments (1–272 aa) interact with mitochondria and may possibly impact on mitochondrial function and cell viability [29]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Both regions are thought to be critical for ApoE4 fragment-related neurotoxicity and mitochondrial impairment, rather than full-length protein [29,31].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“In vitro studies in N2a cells showed that ApoE4 fragments (aa 1–272) interact with mitochondria and cause mitochondrial dysfunction and neurotoxicity [29].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, more recent data suggests the possibility that a fragment of apoE4 (1–272 amino acids), but not full-length apoE4, escapes the secretory pathway, translocates to the cytosolic compartment, and interacts with cytoskeletal components, including tau and neurofilament (Chang et al., 2005).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Chang et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“decreased neurite outgrowth”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“The APOE gene product, interestingly, also appears to influence mitochondrial function [164-167].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Self-citationCellular uptake of the tat protein from human immunodeficiency virus
Frankel, A. D., & Pabo, C. O. (1988) · Cell · doi:10.1016/0092-8674(88)90263-2 · Cited by 2,782
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A. L., Vocero-Akbani, A. M., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,418
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Self-citationGreen, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,551
Berridge, M. V., & Tan, A. S. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1311 · Cited by 1,443
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Research works printed but not linked: 1
- Wisniewski, T., Castaño, E. M., Golabek, A., Vogel, T. & Frangione, B. (1994) Am. J. Pathol. 145, 1030-1035.7977635
Cited by
Sorted by citations
Items 101–200 of 321
Swerdlow, R. H. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.008 · Cited by 88
Roses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
Brodbeck, J., Balestra, M. E., Saunders, A. M., Roses, A. D., Mahley, R. W., & Huang, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709906104 · Cited by 86
Self-citationChhimpa, N., Singh, N., Puri, N., & Kayath, H. P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220514 · Cited by 89
Could Alzheimer’s Disease Originate in the Periphery and If So How So?
Morris, G., Berk, M., Maes, M. H. J., & Puri, B. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1092-y · Cited by 86
Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases
Alagarsamy, J., Jaeschke, A., & Hui, D. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179892 · Cited by 86
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 88
Lott, I. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.12.010 · Cited by 86
Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease?
Su, B., Wang, X., Bonda, D., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8095-7 · Cited by 85
Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.
Huang, Y. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af368 · Cited by 82
Self-citationThe Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 84
Understanding the Role of ApoE Fragments in Alzheimer’s Disease
Muñoz, S. S., Garner, B., & Ooi, L. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2629-1 · Cited by 91
Association of hypometabolism and amyloid levels in aging, normal subjects
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L. G., Kantarci, K., Boeve, B. F., Jack, C. R., Knopman, D. S., & Petersen, R. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000467 · Cited by 83
Buttini, M., Masliah, E., Yu, G.-Q., Palop, J. J., Chang, S., Bernardo, A., Lin, C., Wyss-Coray, T., Huang, Y., & Mucke, L. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090973 · Cited by 80
Self-citationAPOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
Wolf, A. B., Caselli, R. J., Reiman, E. M., & Valla, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.011 · Cited by 84
Lin, H., Han, L., Zhang, H. L., Zheng, C., Xie, B., Cao, Z. F., & Chen, Y. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s5-s13 · Cited by 78
Journal of Parkinson’s disease & Alzheimer’s disease
Gottschalk, W. K., Lutz, M. W., He, Y. T., Saunders, A. M., Burns, D. K., Roses, A. D., & Chiba‐Falek, O. (2014) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000003 · Cited by 80
Cholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 78
Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics
Olivier, I. S., Cacabelos, R., & Naidoo, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113594 · Cited by 74
Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., & Huang, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018381108 · Cited by 71
Self-citationRoses, A., Sundseth, S., Saunders, A., Gottschalk, W., Burns, D., & Lutz, M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.015 · Cited by 70
Longitudinal modeling of cognitive aging and the TOMM40 effect
Caselli, R. J., Dueck, A. C., Huentelman, M. J., Lutz, M. W., Saunders, A. M., Reiman, E. M., & Roses, A. D. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.11.006 · Cited by 69
“The APOE e4 allele influences risk and age of onset of AD in a gene dose-dependent fashion [10], and the apoe e4 isoform itself is toxic to mitochondria [8,11].”
BackgroundRole of PPAR γ in the Differentiation and Function of Neurons
Quintanilla, R. A., Utreras, E., & Cabezas-Opazo, F. (2014) · PPAR Research · doi:10.1155/2014/768594 · Cited by 71
Mitochondrial trafficking and morphology in neuronal injury
Rintoul, G. L., & Reynolds, I. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.09.005 · Cited by 70
Alternative Splicing in Alzheimer’s Disease
Love, J. E., Hayden, E. J., & Rohn, T. T. (2015) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000010 · Cited by 69
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Mitochondrial Metabolism in Major Neurological Diseases
Zhou, Z., Austin, G. L., Young, L. E. A., Johnson, L. A., & Sun, R. C. (2018) · Cells · doi:10.3390/cells7120229 · Cited by 67
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
Dai, J., Johnson, E. C. B., Dammer, E. B., Duong, D. M., Gearing, M., Lah, J. J., Levey, A. I., Wingo, T. S., & Seyfried, N. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00454 · Cited by 62
Dammer, E. B., Shantaraman, A., Ping, L., Duong, D. M., Gerasimov, E. S., Ravindran, S. P., Guðmundsdóttir, V., Frick, E. A., Gómez, G., Walker, K. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn3504 · Cited by 63
Wilkins, H., Koppel, S. J., Bothwell, R. J., Mahnken, J. D., Burns, J. M., & Swerdlow, R. H. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.010 · Cited by 61
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Rethinking Alzheimer's Disease Therapy: Are Mitochondria the Key?
Ankarcrona, M., Mangialasche, F., & Winblad, B. G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100327 · Cited by 60
New applications of disease genetics and pharmacogenetics to drug development
Roses, A. D., Saunders, A. M., Lutz, M. W., Zhang, N., Hariri, A. R., Asin, K. E., Crenshaw, D. G., Budur, K. S., Burns, D. K., & Brannan, S. K. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.12.002 · Cited by 59
Apolipoprotein E-genotype dependent hippocampal and cortical responses to traumatic brain injury
Crawford, F., Wood, M., Ferguson, S., Mathura, V., Gupta, P., Humphrey, J., Mouzon, B., Laporte, V., Margenthaler, E., O'Steen, B., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.033 · Cited by 59
The hereditary spastic paraplegia protein spartin localises to mitochondria
Lu, J., Rashid, F., & Byrne, P. C. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04008.x · Cited by 58
Apolipoprotein E and Neurological Disease: Therapeutic Potential and Pharmacogenomic Interactions
Laskowitz, D. T., & Vitek, M. P. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.959 · Cited by 58
Isoform-specific proteolysis of apolipoprotein-E in the brain
Elliott, D. A., Tsoi, K., Holinkova, S., Chan, S. L., Kim, W. S., Halliday, G. M., Rye, K., & Garner, B. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.006 · Cited by 59
Rohn, T. T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714908 · Cited by 58
Alzheimer disease and the periodontal patient: New insights, connections, and therapies
Ryder, M. I., & Xenoudi, P. (2021) · Periodontology 2000 · doi:10.1111/prd.12389 · Cited by 55
Apolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease
Wolf, A. B., Valla, J., Bu, G., Kim, J., LaDu, M., Reiman, E. M., & Caselli, R. J. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt204 · Cited by 55
Area-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
Senescence-Accelerated Mice P8: A Tool to Study Brain Aging and Alzheimer's Disease in a Mouse Model
Pallàs, M. (2012) · ISRN Cell Biology · doi:10.5402/2012/917167 · Cited by 57
Zheng, J., Sun, J., Ji, C.-M., Shen, L., Chen, Z.-J., Xie, P., Sun, Y.-Z., & Yu, R. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.002 · Cited by 54
The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease
Zeitlow, K., Charlambous, L., Ng, I., Gagrani, S., Mihovilovic, M., Luo, S., Rock, D. L., Saunders, A. M., Roses, A. D., & Gottschalk, W. K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.031 · Cited by 56
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Mitochondrial links between brain aging and Alzheimer’s disease
Wilkins, H., & Swerdlow, R. H. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00261-2 · Cited by 53
Mahley, R. W., & Huang, Y. (2009) · Annals of Neurology · doi:10.1002/ana.21736 · Cited by 53
Self-citationApolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis
Wilhelmus, M. M. M., Bol, J. G. J. M., van Haastert, E. S., Rozemüller, A. J. M., Bu, G., Drukarch, B., & Hoozemans, J. J. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.07.021 · Cited by 52
Triad of Risk for Late Onset Alzheimer’s: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex
Wang, Y., & Brinton, R. D. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00232 · Cited by 52
Proteomic Analysis of Mitochondria in APOE Transgenic Mice and in Response to an Ischemic Challenge
James, R., Searcy, J. L., Bihan, T. L., Martin, S. F., Gliddon, C. M., Povey, J. E., Deighton, R. F., Kerr, L. E., McCulloch, J., & Horsburgh, K. J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.120 · Cited by 51
TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity
Maruszak, A., Pepłońska, B., Safranow, K., Chodakowska-Żebrowska, M., Barcikowska, M., & Żekanowski, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110743 · Cited by 50
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobričić, V., Bos, I., Vos, S. J. B., Tsolaki, M., Verhey, F. R. J., Popp, J., Martínez‐Lage, P., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00628-z · Cited by 50
Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury
Jiang, L., Zhong, J., Dou, X., Cheng, C., Huang, Z., & Sun, X. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.005 · Cited by 50
Huang, Y. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390924 · Cited by 53
Self-citationWalia, V., Kaushik, D., Mittal, V., Kumar, K., Verma, R., Parashar, J., Akter, R., Rahman, M. H., Bhatia, S., Al-Harrasi, A., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02617-1 · Cited by 47
Bohnen, J. L. B., Albin, R. L., & Bohnen, N. I. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1123290 · Cited by 47
Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?
Wirz, K. T. S., Keitel, S., Swaab, D. F., Verhaagen, J., & Bossers, K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130920 · Cited by 47
Calderón‐Garcidueñas, L., & de la Monte, S. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161299 · Cited by 50
Structural and functional variations in human apolipoprotein E3 and E4.
Chou, C.-Y., Jen, W.-P., Hsieh, Y.-H., Shiao, M.-S., & Chang, G.-G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511077200 · Cited by 46
Kosmopoulou, D., Lafara, M.-P., Adamantidi, T., Ofrydopoulou, A., Grabrucker, A. M., & Τσούπρας, Α. (2024) · Applied Sciences · doi:10.3390/app14156417 · Cited by 45
Calderón‐Garcidueñas, L., González-Maciel, A., Kulesza, R. J., González‐González, L. O., Reynoso-Robles, R., Mukherjee, P. S., & Torres‐Jardón, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190331 · Cited by 46
Tukhovskaya, E. A., Yukin, A. Y., Khokhlova, O. N., Murashev, A. N., & Vitek, M. P. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21874 · Cited by 44
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
Effect of Carboxyl-Terminal Truncation on Structure and Lipid Interaction of Human Apolipoprotein E4
Tanaka, M., Vedhachalam, C., Sakamoto, T., Dhanasekaran, P., Phillips, M. C., Lund-Katz, S., & Saito, H. (2006) · Biochemistry · doi:10.1021/bi060023b · Cited by 43
Mahley, R. W. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102684 · Cited by 43
Self-citationAPOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline
Fang, W., Xiao, N., Zeng, G., Bi, D., Dai, X., Mi, X., Ye, Q., Chen, X., & Zhang, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01631-0 · Cited by 42
Bennett, R. E., Esparza, T. J., Lewis, H. A., Kim, E., Mac Donald, C. L., Sullivan, P. M., & Brody, D. L. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31828e24ab · Cited by 40
Fritsche, L. G., Freitag‐Wolf, S., Bettecken, T., Meitinger, T., Keilhauer, C. N., Krawczak, M., & Weber, B. H. F. (2008) · Human Mutation · doi:10.1002/humu.20957 · Cited by 43
Sawmiller, D. R., Li, S., Mori, T., Habib, A., Rongo, D., Delic, V., Bradshaw, P. C., Shytle, R. D., Sanberg, C. D., Bickford, P. C., et al. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00279 · Cited by 42
An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42
Dafnis, I., Stratikos, E., Tzinia, A., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06756.x · Cited by 41
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
Apolipoprotein E Mimetics and Cholesterol-Lowering Properties
Sharifov, O. F., Nayyar, G., Garber, D. W., Handattu, S. P., Mishra, V., Goldberg, D., Anantharamaiah, G. M., & Gupta, H. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11594190-000000000-00000 · Cited by 41
Persson, T., Lattanzio, F., Calvo‐Garrido, J., Rimondini, R., Rubio-Rodrigo, M., Sundström, E., Maioli, S., Matton, A., & Cedazo-Mı́nguez, Á. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150738 · Cited by 44
Jain, S., Yoon, S. Y., Leung, L., Knöferle, J., & Huang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059478 · Cited by 39
Self-citationThai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D. J., Ellis, K. A., Rainey‐Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts
Swerdlow, R. H., Hui, D., Chalise, P., Sharma, P., Wang, X., Andrews, S. J., Pa, J., Mahnken, J. D., Morris, J. K., Wilkins, H., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12119 · Cited by 39
Lin, H., Han, L., Zhang, H. L., Zheng, C., Xie, B., & Chen, Y. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500530-jlr200 · Cited by 39
Concerning the structure of apoE
Frieden, C., & Garai, K. (2013) · Protein Science · doi:10.1002/pro.2379 · Cited by 39
Alzheimer’s disease: diagnostics, prognostics and the road to prevention
Grossman, I., Lutz, M. W., Crenshaw, D. G., Saunders, A. M., Burns, D. K., & Roses, A. D. (2010) · EPMA Journal · doi:10.1007/s13167-010-0024-3 · Cited by 37
Roses, A. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.153 · Cited by 37
To, A. W. M., Ribé, E. M., Chuang, T. T., Schroeder, J. E., & Lovestone, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016991 · Cited by 37
African‐American TOMM40'523‐APOE haplotypes are admixture of West African and Caucasian alleles
Roses, A. D., Lutz, M. W., Saunders, A. M., Goldgaber, D., Saul, R., Sundseth, S. S., Akkari, P. A., Roses, S. M., Gottschalk, W. K., Whitfield, K. E., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.06.009 · Cited by 36
Jablonski, A. M., Warren, L., Usenovic, M., Zhou, H. H., Sugam, J. A., Parmentier‐Batteur, S., & Voleti, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-82901-1 · Cited by 38
The Interplay Between Apolipoprotein E4 and the Autophagic–Endocytic–Lysosomal Axis
Schmukler, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0892-4 · Cited by 35
Fote, G. M., Geller, N. R., Efstathiou, N. E., Hendricks, N., Vavvas, D. G., Reidling, J. C., Thompson, L. M., & Steffan, J. S. (2022) · Journal of Cell Science · doi:10.1242/jcs.258687 · Cited by 36
Lane, R. F., Shineman, D. W., Steele, J., Lee, L. H., & Fillit, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00007-6 · Cited by 35
Dafnis, I., Tzinia, A. K., Tsilibary, E. C., Zannis, V. I., & Chroni, A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.013 · Cited by 32
Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function
Rueter, J., Rimbach, G. H., & Huebbe, P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04516-7 · Cited by 32
The Role of Upregulated APOE in Alzheimer's Disease Etiology
Gottschalk, W. K., & Mihovilovic, M. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000209 · Cited by 33
Fleck, D., Phu, L., Verschueren, E., Hinkle, T. B., Reichelt, M., Bhangale, T., Haley, B., Wang, Y., Graham, R., Kirkpatrick, D. S., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0116-19.2019 · Cited by 31
Argyri, L., Dafnis, I., Theodossiou, T. A., Gantz, D., Stratikos, E., & Chroni, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538124 · Cited by 30
Perspective on a pathogenesis and treatment of Alzheimer's disease
Roses, A. D., & Saunders, A. M. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.12.001 · Cited by 30
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Anandatheerthavarada, H. K., & Devi, L. (2007) · Reviews in the Neurosciences · doi:10.1515/revneuro.2007.18.5.343 · Cited by 28
Saul, A., & Wirths, O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9674-4 · Cited by 28
Burggren, A. C., Mahmood, Z., Harrison, T. M., Siddarth, P., Miller, K. J., Small, G. W., Merrill, D. A., & Bookheimer, S. Y. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.009 · Cited by 27
Chroni, A., Pyrpassopoulos, S., Thanassoulas, A., Nounesis, G., Zannis, V. I., & Stratikos, E. (2008) · Biochemistry · doi:10.1021/bi800469r · Cited by 26
Cerantonio, A., Citrigno, L., Greco, B. M., Benedittis, S. D., Passarino, G., Maletta, R., Qualtieri, A., Montesanto, A., Spadafora, P., & Cavalcanti, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116062 · Cited by 25
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
Muñoz, S. S., Li, H., Ruberu, K. R., Chu, Q., Saghatelian, A., Ooi, L., & Garner, B. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001278 · Cited by 24
Metadata
- Authors
- Chang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y.
- Affiliations
- University of California, San Francisco (US)
- Gladstone Institutes (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-12-12
- Volume
- 102
- Issue
- 51
- Pages
- 18694-18699
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1311737
- OpenAlex
- W2022943683
- Cited by
- 319
- References
- 73
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 15 · 2023: 16 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 21 · 2018: 13 · 2017: 14 · 2016: 18 · 2015: 10 · 2014: 15 · 2013: 19 · 2012: 18
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Institutes of Health (AG‐022074)
- National Institute on Aging (P01AG022074)
- National Heart, Lung, and Blood Institute (R01 HL37063, R01HL037063)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- APOE ε4, neurotoxicity, mitochondrial dysfunction, receptor-binding region, Alzheimer's disease, tau phosphorylation, N2a cells, transgenic mice
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Cytoskeleton, Lipids, Mitochondria, Mutation, Neurons, Peptide Fragments, Receptors, Lipoprotein, Cell Line, Tumor, Mice, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
